Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GLP1R | P43220 | 8/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2743011 | 0.98 | GLP1R (0.37) | MEN1KMT2AGLP1RSMN1; SMN2TSHR | |
| SCHEMBL2743010 | 0.93 | SMN1; SMN2 (0.43) | MEN1KMT2AGLP1RSMN1; SMN2TSHR | |
| SCHEMBL13689237 | 0.89 | GLP1R (0.39) | MEN1KMT2AGLP1RSMN1; SMN2TSHR | |
| SCHEMBL7950916 | 0.89 | MEN1 (0.42) | MEN1KMT2ASMN1; SMN2TSHRMAPK1 | |
| SCHEMBL27409309 | 0.88 | TSHR (0.44) | GLP1RSMN1; SMN2TSHRMAPK1RECQL | |
| SCHEMBL24855312 | 0.84 | GLP1R (0.43) | MEN1KMT2AGLP1RSMN1; SMN2TSHR | |
| SCHEMBL13062338 | 0.84 | MEN1 (0.38) | MEN1KMT2AGLP1RSMN1; SMN2TSHR | |
| SCHEMBL422917 | 0.84 | GLP1R (0.38) | MEN1KMT2AGLP1RSMN1; SMN2TSHR | |
| SCHEMBL13274091 | 0.84 | GLP1R (0.41) | MEN1KMT2AGLP1RSMN1; SMN2TSHR | |
| SCHEMBL18723358 | 0.84 | GLP1R (0.46) | MEN1KMT2AGLP1RSMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415510-B2 | Synthesis of a PEG-6 moiety from commercial low-cost chemicals | GE HEALTHCARE LIMITED (GB) | 2013-04-09 | — | — | US | claimed |
| EP-2268609-B1 | Synthesis of a PEG-6 moiety from commercial low-cost chemicals | GE HEALTHCARE LTD (GB) | 2013-01-30 | — | — | EP | claimed |
| EP-2268609-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GE Healthcare Limited (GB) | 2011-01-05 | — | — | EP | claimed |
| US-20100324264-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GE HEALTHCARE LIMITED (GB) | 2010-12-23 | — | — | US | claimed |
| WO-2009108484-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GE HEALTHCARE LIMITED (GB) | 2009-09-03 | — | — | WO | claimed |
| US-8536375-B2 | Synthesis of obtaining modified polyethylene glycol intermediates | GE HEALTHCARE LIMITED (GB) | 2013-09-17 | — | — | US | disclosed |
| US-8536375-B2 | Synthesis of obtaining modified polyethylene glycol intermediates | GE HEALTHCARE LIMITED (GB) | 2013-09-17 | — | — | US | disclosed |
| US-8536375-B2 | Synthesis of obtaining modified polyethylene glycol intermediates | GE HEALTHCARE LIMITED (GB) | 2013-09-17 | — | — | US | disclosed |
| US-8415510-B2 | Synthesis of a PEG-6 moiety from commercial low-cost chemicals | GE HEALTHCARE LIMITED (GB) | 2013-04-09 | — | — | US | disclosed |
| US-8415510-B2 | Synthesis of a PEG-6 moiety from commercial low-cost chemicals | GE HEALTHCARE LIMITED (GB) | 2013-04-09 | — | — | US | disclosed |
| US-8415510-B2 | Synthesis of a PEG-6 moiety from commercial low-cost chemicals | GE HEALTHCARE LIMITED (GB) | 2013-04-09 | — | — | US | disclosed |
| EP-2268609-B1 | Synthesis of a PEG-6 moiety from commercial low-cost chemicals | GE HEALTHCARE LTD (GB) | 2013-01-30 | — | — | EP | disclosed |
| US-20120004423-A1 | SYNTHESIS OF OBTAINING MODIFIED POLYETHYLENE GLYCOL INTERMEDIATES | GE HEALTHCARE LIMITED (GB) | 2012-01-05 | — | — | US | disclosed |
| EP-2370501-A1 | SYNTHESIS OF OBTAINING MODIFIED POLYETHYLENE GLYCOL INTERMEDIATES | GE Healthcare Limited (GB) | 2011-10-05 | — | — | EP | disclosed |
| EP-2268609-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GE Healthcare Limited (GB) | 2011-01-05 | — | — | EP | disclosed |
| US-20100324264-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GE HEALTHCARE LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| US-20100324264-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GE HEALTHCARE LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| US-20100324264-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GE HEALTHCARE LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| WO-2010074935-A1 | SYNTHESIS OF OBTAINING MODIFIED POLYETHYLENE GLYCOL INTERMEDIATES | GE HEALTHCARE LIMITED (GB) | 2010-07-01 | — | — | WO | disclosed |
| WO-2009108484-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GE HEALTHCARE LIMITED (GB) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004423-A1 | SYNTHESIS OF OBTAINING MODIFIED POLYETHYLENE GLYCOL INTERMEDIATES | COASY, DHPS, FASN | MEN1 2396/4885KMT2A 2028/4885GLP1R 3094/4885 |
| US-20100324264-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GAS6, LNPEP, BMP6 | MEN1 2158/4885KMT2A 1884/4885GLP1R 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.